Drug manufacturer Daiichi-Sankyo is offering 340B covered entities refunds for overcharges on metastatic breast cancer treatment Enhertu during Q1 2020 and on cholesterol medication Welchol for Oral Suspension during Q1 2022 and Q4 2022.
The U.S. Health Resources and Services
…
U.S. Rep. Larry Bucshon (R-Ind.), vice chair of the House Energy & Commerce health subcommittee, has written a bill to impose significant 340B program reporting requirements on disproportionate share hospitals and potentially other covered entities. Meanwhile, two bills have been
…
U.S. Health Resources and Services Administration Administrator Carole Johnson said on Capitol Hill yesterday that HRSA would welcome congressional help ensuring there is “accountability and transparency” in the 340B program.
Johnson was answering questions from Rep. Morgan Griffith (R-Va.) during
…
Three groups representing 340B hospitals late last week filed an amicus brief in federal circuit court in support of Arkansas’ novel contract pharmacy law, arguing the law doesn’t conflict with the 340B statute and in fact furthers the goals of
…
A Philadelphia-area hospital that closed last year after its sale fell through has filed a federal antitrust class action against healthcare conglomerate CVS over its 340B contract pharmacy policies.
The same shuttered hospital has been challenging in state court its
…
The federal government yesterday decided not to ask all 14 judges on the U.S. Third Circuit Court of Appeals in Philadelphia to review a three-judge panel’s unanimous January opinion upholding AstraZeneca, Novo Nordisk, and Sanofi’s restrictions on 340B pricing when
…
Drug manufacturer Eli Lilly asked a 340B covered entity last week to promptly repay it for “duplicate 340B/Medicaid discounts” and evaluate all Lilly prescriptions that it or its contract pharmacies dispensed for the last three years.
Consultants and attorneys with
…
About a dozen people who advise, help run, or work at 340B covered entities are launching a nonprofit group, 340B Truth, to try to hammer out a covered entity consensus position on 340B reform and urge Congress to pass it
…
The U.S. Department of Health and Human Services Office of Inspector General said yesterday it has no comment on the status of referrals from the U.S. Health Resources and Services Administration to fine eight drug manufacturers for failing to offer
…
The state of Arkansas and Arkansas 340B covered entities separately asked a federal appeals court yesterday to back a judge’s decision in December that the state’s novel 340B anti-discrimination law is not preempted by the 340B statute nor by the
…*Sign up for news summaries and alerts from 340B Report